Does EVOLOCUMAB Cause Therapy cessation? 299 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 299 reports of Therapy cessation have been filed in association with EVOLOCUMAB (REPATHA). This represents 0.2% of all adverse event reports for EVOLOCUMAB.
299
Reports of Therapy cessation with EVOLOCUMAB
0.2%
of all EVOLOCUMAB reports
4
Deaths
86
Hospitalizations
How Dangerous Is Therapy cessation From EVOLOCUMAB?
Of the 299 reports, 4 (1.3%) resulted in death, 86 (28.8%) required hospitalization, and 4 (1.3%) were considered life-threatening.
Is Therapy cessation Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for EVOLOCUMAB. However, 299 reports have been filed with the FAERS database.
What Other Side Effects Does EVOLOCUMAB Cause?
Device difficult to use (31,807)
Drug dose omission by device (23,957)
Wrong technique in product usage process (21,664)
Accidental exposure to product (16,160)
Injection site pain (9,988)
Product storage error (6,606)
Back pain (5,254)
Myalgia (5,061)
Drug dose omission (4,914)
Injection site bruising (4,409)
What Other Drugs Cause Therapy cessation?
DALFAMPRIDINE (4,580)
ETANERCEPT (2,031)
ADALIMUMAB (1,712)
ABIRATERONE (1,602)
VOXELOTOR (1,038)
CLOZAPINE (885)
LOMITAPIDE (828)
CAPECITABINE (746)
TREPROSTINIL (743)
ISOTRETINOIN (633)
Which EVOLOCUMAB Alternatives Have Lower Therapy cessation Risk?
EVOLOCUMAB vs EXELON
EVOLOCUMAB vs EXEMESTANE
EVOLOCUMAB vs EXENATIDE
EVOLOCUMAB vs EXFORGE
EVOLOCUMAB vs EXJADE